Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment

Stevenson, Julia; Barrow-McGee, Rachel; Lu, Yu; Paul, Angela; Mansfield, David; Owen, Julie; Woodman, Natalie; Natrajan, Rachael; Haider, Syed; Gillett, Cheryl; Tutt, Andrew; Pinder, Sarah; Choudary, Jyoti; Naidoo, Khimara

doi:10.1038/s41523-021-00227-7

Cited by 5 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another comparative study, Stevenson et al. showed that ALDH1A1, ALDH2, and ALDH9A1 proteins are present in LNM specimens from breast cancer, PDAC and PCa, indicating a potential common role of these proteins in the development of LNM 233 …”

Section: Aldhs As Csc and Prognosis Markers In Tumorsmentioning

confidence: 99%

Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets

Xia

Liu

et al. 2023

MedComm

View full text Add to dashboard Cite

The family of aldehyde dehydrogenases (ALDHs) contains 19 isozymes and is involved in the oxidation of endogenous and exogenous aldehydes to carboxylic acids, which contributes to cellular and tissue homeostasis. ALDHs play essential parts in detoxification, biosynthesis, and antioxidants, which are of important value for cell proliferation, differentiation, and survival in normal body tissues. However, ALDHs are frequently dysregulated and associated with various diseases like Alzheimer's disease, Parkinson's disease, and especially solid tumors. Notably, the involvement of the ALDHs in tumor progression is responsible for the maintenance of the stem‐cell‐like phenotype, triggering rapid and aggressive clinical progressions. ALDHs have captured increasing attention as biomarkers for disease diagnosis and prognosis. Nevertheless, these require further longitudinal clinical studies in large populations for broad application. This review summarizes our current knowledge regarding ALDHs as potential biomarkers in tumors and several non‐tumor diseases, as well as recent advances in our understanding of the functions and underlying molecular mechanisms of ALDHs in disease development. Finally, we discuss the therapeutic potential of ALDHs in diseases, especially in tumor therapy with an emphasis on their clinical implications.

show abstract

Section: Aldhs As Csc and Prognosis Markers In Tumorsmentioning

confidence: 99%

Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets

Xia

Liu

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…Verma and colleagues compared the transcriptomic profile of LNCaP cells with an acquired enzalutamide resistance with their parental counterparts and found the downregulation of ALDH9A1 expression in the resistance cells [ 162 ]. In another comparative study, Stevenson et al showed that ALDH1A1, ALDH2, and ALDH9A1 proteins are present in lymph node metastasis specimens of breast cancer, pancreatic ductal adenocarcinoma, and prostate cancer, indicating a potential common role of these proteins in the development of lymph node metastases in patients with different tumor entities [ 163 ]. Additionally, ALDH9A1 was shown to be associated with a biochemical recurrence in the Cancer Genome Atlas prostate adenocarcinoma (TCGA-PRAD) dataset [ 164 ].…”

Section: Aldh9a1mentioning

confidence: 99%

The Multifaceted Role of Aldehyde Dehydrogenases in Prostate Cancer Stem Cells

Püschel

Dubrovska

Gorodetska

2021

Cancers

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are the only tumor cells possessing self-renewal and differentiation properties, making them an engine of tumor progression and a source of tumor regrowth after treatment. Conventional therapies eliminate most non-CSCs, while CSCs often remain radiation and drug resistant, leading to tumor relapse and metastases. Thus, targeting CSCs might be a powerful tool to overcome tumor resistance and increase the efficiency of current cancer treatment strategies. The identification and isolation of the CSC population based on its high aldehyde dehydrogenase activity (ALDH) is widely accepted for prostate cancer (PCa) and many other solid tumors. In PCa, several ALDH genes contribute to the ALDH activity, which can be measured in the enzymatic assay by converting 4, 4-difluoro-4-bora-3a, 4a-diaza-s-indacene (BODIPY) aminoacetaldehyde (BAAA) into the fluorescent product BODIPY-aminoacetate (BAA). Although each ALDH isoform plays an individual role in PCa biology, their mutual functional interplay also contributes to PCa progression. Thus, ALDH proteins are markers and functional regulators of CSC properties, representing an attractive target for cancer treatment. In this review, we discuss the current state of research regarding the role of individual ALDH isoforms in PCa development and progression, their possible therapeutic targeting, and provide an outlook for the future advances in this field.

show abstract